, / PRNewswire / – High-tech Advanced Electrophoresis Solutions Ltd. (AES) based in Cambridge secured a pre-A investment that closed in April to address critical QA / QC bottlenecks at Biopharma.
This round was the first AES institutional growth, led by GCI Capital and Celtic House Asia Partners of Toronto. GCI Capital provided strategic advice through its subsidiary G-Force Innovation Hub to help AES accelerate its sales in the global marketplace.
Founded in 2010 by Dr. Tiemin Huang, Advanced Electrophoresis Solutions Ltd. becomes a complete provider of iCIEF technology solutions serving the biopharmaceutical and protein chemistry industries. Dr. Huang has nearly 40 years of experience in analytical chemistry with the development of analytical methodology. After earning his doctorate from the University of Waterloo in 2003, he joined the pioneering company iCIEF Convergent Bioscience LTD. and has been involved in several critical early innovations in iCIEF technology. The innovations he transferred to AES continued to evolve over the next 20 years and evolved into the current version of AES products.
AES’s product portfolio includes instruments (analytical and preparative iCIEF and mass spectrometry interface), critical reagents, application & amp; workflow and contractual service. AES works with leading biopharmaceutical companies in the world and plays a key role with many customers in terms of essential QA / QC for commercialized products and FDA preparation for new drug applications.
AES’s patented Capillary Diameter Transformation Technique (CDTT) can achieve high resolution and highly efficient iCIEF fractionation, providing a fractionation service with a bulk filling variant.
Critical reagents provided by AES, including high-performance carrier ampholytes for mAb, ADC, bispecific antibodies, fusion protein, and next-generation biopharmaceuticals as cell-based and gene therapy with good batch-to-batch consistency, have saved millions of customers and significantly shortened hours. AES can also adjust reagent / consumables based on customer criteria.
In 2021, AES established a strategic global partnership with Thermo Fisher Scientific in tandem high-resolution mass spectrometry capillary electrophoresis that characterizes protein drugs and vaccines. In addition, iCIEF and its connection to the orbitrap MS platform in AES’s CEC Laboratory (Customer Experience Center Lab) can contribute to our customers ’urgent needs in biopharmacy development, including the iCIEF analytical method, protein preparation variant and ampere; identification and customer service.
The above values from the AES breakthrough outweigh the challenges in protein chemistry that current methodologies cannot solve.
SOURCE Advanced electrophoresis solutions